BioInformant

Your Global Leader in Stem Cell Market Research

Home » regenerative medicine

Top 8 Stem Cell Quotes of All-Time

By Leave a Comment

Many experts have spoken about the power of stem cells and their ability to alter the field of healthcare forever, including these top stem cell quotes of all-time. With exponential progress occurring in the field, stem cells are ushering in an age of regenerative medicine that will transform healthcare in ways that are now inconceivable.

In coming decades, stem cells will be reversing diseases ranging from Alzheimer’s to autism, re-growing organs and tissues, and potentially allowing the first humans to reach the age of 200.

Some exciting advances with stem cells include these “science fictions” that have become “science facts”: [Read more…]

A Timeline of Landmark Events in the Stem Cell Industry

By Leave a Comment

Research and experimentation have been driving progress within the stem cell industry for decades. Despite major advances in stem cell knowledge, current medical approaches still rely heavily on pharmaceuticals and a surgeon’s scalpel. There is irony in the term “modern” medicine, because its central focus has largely been to address symptoms and not underlying medical issues. “Diabetic? No problem, we can regulate your insulin.”

Under our current framework for medicine, regenerative medicine has not played a central role.
[Read more…]

U.S. FDA Approved RMATs on the Rise

By Leave a Comment

With recent news from Sangamo Therapeutics and Krystal Biotech, the count of announced RMAT (“Regenerative Medicine Advanced Therapy”) designations has risen to 30.

Krystal Biotech received an RMAT designation for its gene therapy KB103 on June 24, 2019. KB103 is being studied for its wound closure capacity in patients with severe generalized recessive dystrophic epidermolysis bullosa (“RDEB”). The FDA also granted a RMAT designation for Sangamo Therapeutics’ SB-525, an investigational gene therapy being developed in collaboration with Pfizer to treat severe hemophilia A. SB-525 is the first hemophilia A gene therapy to receive RMAT designation. [Read more…]

Definition of the Regenerative Medicine Industry?

By Leave a Comment

The Regenerative Medicine (RM) Industry is a rapidly growing market with more than 700+ companies worldwide developing products for therapeutic for use in humans. As with any growing industry, the question becomes, how do you define the Regenerative Medicine Industry?

To answer this question, it is important to look at the key components that compose the human body, which are:

  • Genes
  • Cells
  • Tissues
  • Organs

[Read more…]

RegMed Innovative Spikes on Heels of CAR-T, Gene Therapy, & Digital Pill Approvals

By Leave a Comment

The regenerative medicine industry is a high-value, fast-growth market. With two CAR-T approvals, as well as the first gene therapy and digital pill approvals in the United States, we have had a lot of FDA “firsts.” The market gathered momentum when the Swiss pharmaceutical giant Novartis made history as the first company to win FDA approval for a CAR-T cell therapy in the U.S. in August 2017 (Kymriah). In October 2017, Kite Pharma became the second company to get FDA approval of a CAR-T cell therapy (Yescarta), further “snowballing” the effect. [Read more…]

BioInformant's World-Class Clients

Shopping cart0
There are no products in the cart!
Continue shopping
0